var data={"title":"Capsaicin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Capsaicin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5806?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=capsaicin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Capsaicin: Patient drug information&quot;</a> and <a href=\"topic.htm?path=capsaicin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Capsaicin: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145291\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Aflexeryl-MC [OTC] [DSC];</li>\n      <li>Aleveer [OTC] [DSC];</li>\n      <li>Allevess [OTC];</li>\n      <li>Captracin [DSC];</li>\n      <li>Capzasin-HP [OTC];</li>\n      <li>Capzasin-P [OTC];</li>\n      <li>DiabetAid Pain and Tingling Relief [OTC];</li>\n      <li>Flexin;</li>\n      <li>Levatio;</li>\n      <li>MaC Patch;</li>\n      <li>MenCaps [OTC];</li>\n      <li>Neuvaxin [DSC];</li>\n      <li>Qroxin [DSC];</li>\n      <li>Qutenza;</li>\n      <li>Releevia;</li>\n      <li>Releevia MC;</li>\n      <li>RelyyT [DSC];</li>\n      <li>Renovo;</li>\n      <li>Salonpas Gel-Patch Hot [OTC];</li>\n      <li>Salonpas Hot [OTC] [DSC];</li>\n      <li>Sinelee [DSC];</li>\n      <li>Solaice [DSC];</li>\n      <li>Sure Result SR Relief [OTC];</li>\n      <li>Trixaicin HP [OTC];</li>\n      <li>Trixaicin [OTC] [DSC];</li>\n      <li>Zostrix Arthritis Pain Relief [OTC] [DSC];</li>\n      <li>Zostrix Diabetic Foot Pain [OTC] [DSC];</li>\n      <li>Zostrix Diabetic Pain Relief [OTC] [DSC];</li>\n      <li>Zostrix Foot Pain Relief [OTC] [DSC];</li>\n      <li>Zostrix [OTC] [DSC];</li>\n      <li>Zostrix-HP [OTC]</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145292\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Zostrix;</li>\n      <li>Zostrix H.P.</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145311\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Analgesic, Topical;</li>\n      <li>\n        Topical Skin Product;</li>\n      <li>\n        Transient Receptor Potential Vanilloid 1 (TRPV1) Agonist</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145293\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Muscle/joint pain:</b> Topical:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cream, gel, liquid, lotion: Apply thin film to affected areas 3 to 4 times daily.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Patch:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">0.025%, 0.03%, 0.0375%, 0.05% (Sinelee only):  Apply 1 patch to affected area for up to 8 hours (maximum: 4 patches/day); do not use for &gt;5 consecutive days (product specific)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">0.05% (Solaice only): Apply 1 patch to affected area for up to 8 hours (maximum: 4 patches/day)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Neuropathic pain:</b> Topical: Patch (Qutenza): Apply patch to most painful area for 60 minutes. Up to 4 patches may be applied in a single application. Treatment may be repeated &ge;3 months as needed for return of pain (do not apply more frequently than every 3 months). Area should be pretreated with a topical anesthetic prior to patch application.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diabetic neuropathy (off-label use):</b> Topical: Cream (0.075%): Apply 4 times/day (Bril 2011)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145302\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=capsaicin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Capsaicin: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Muscle/joint pain:</b> Topical: Patch:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">0.025%, 0.03%, 0.0375%, 0.05% (Sinelee only): Children &ge;12 years and Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">0.05% (Solaice only): Adolescents &ge;16 years: Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145294\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45627595\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45627596\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;margin-left:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145280\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cream, topical:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Capzasin-HP: 0.1% (42.5 g) [contains benzyl alcohol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Capzasin-P: 0.035% (42.5 g) [contains benzyl alcohol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Sure Result SR Relief: 0.025% (118 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Trixaicin: 0.025% (60 g [DSC]) [contains benzyl alcohol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Trixaicin HP: 0.075% (60 g) [contains benzyl alcohol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Zostrix HP: 0.1% (60 g) [contains benzyl alcohol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Zostrix Maximum Strength Natural Pain Relief: 0.1% (56.6 g) [contains benzyl alcohol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Zostrix Maximum Strength Natural Foot Pain Relief: 0.1% (56.6 g) [contains benzyl alcohol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Zostrix Original Strength Natural Pain Relief: 0.033% (56.6 g) [contains benzyl alcohol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Generic: 0.025% (60 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gel, topical:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Capzasin-P: 0.025% (42.5 g) [contains menthol]</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Liquid, topical:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Capzasin-P: 0.15% (29.5 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lotion, topical:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">DiabetAid Pain and Tingling Relief: 0.025% (120 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Patch, topical:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Aflexeril MC: 0.0375% (15s [DSC]) [contains menthol 5%]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Allevess: 0.05% (15s) [contains menthol 5%]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Aleveer: 0.0375% (15s) [contains menthol 5%, and aloe] [DSC]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Captracin: 0.0375% (15s [DSC]) [contains menthol 5%]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Flexin: 0.0375% (15s) [contains menthol 5%]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Levatio: 0.03% (15s) [contains menthol 5%]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">MaC Patch: 0.0375% (15s) [contains menthol 5%]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">MenCaps: 0.0225% (15s) [contains menthol 4.5%]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuvaxin: 0.0375% (15s [DSC]) [contains menthol 5%]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Qroxin: 0.0375% (15s [DSC]) [contains menthol 5%]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Qutenza: 8% (1s, 2s) [contains metal; supplied with cleansing gel]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Releevia: 0.0375% (15s) [contains menthol 5%]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Releevia MC: 0.0375% (15s) [contains menthol 5%]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">RelyyT: 0.025% (15s [DSC]) [contains menthol 5%]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renovo: 0.0375% (15s) [contains menthol 5%]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Sinelee: 0.0375%, 0.05% (15s [DSC]) [contains menthol 5%]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Solaice: 0.05% (15s [DSC]) [contains menthol 5%]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Salonpas Gel-Patch Hot: 0.025% (3s, 6s) [contains menthol]</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Salonpas Hot: 0.025% (1s [DSC]) [contains natural rubber/natural latex in packaging]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145268\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes: Cream</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145282\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Topical products (cream, gel, liquid, lotion): Gently rub into painful area until thoroughly absorbed. Wash hands with soap and water immediately after applying (unless hands are part of the treatment area). If applying cream to hands, wait 30 minutes before washing hands.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Topical patch: Apply patch externally to clean and dry affected area. Remove protective film prior to application. May cut patch to desired size prior to removing the film (product specific). Do not use within 1 hour prior to a bath or immediately after bathing. Do not use with a heating pad.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Topical patch (Qutenza): Patch should only be applied by a health care provider. The treatment area must be identified and marked by a physician. May cut patch to match size/shape of treatment area. If necessary, excessive hair present on and surrounding the treatment area, may be clipped (not shaved). Prior to application, the treatment area should be cleansed with mild soap and water and dried thoroughly. The treatment area and surrounding 1 to 2 cm should be anesthetized with a topical anesthetic prior to patch application; keep the local anesthetic in place until the skin is anesthetized and then remove with a dry wipe; cleanse area again with soap/water, and dry thoroughly. Patch may then be applied to dry, intact skin within 2 hours of opening the patch; apply patch using nitrile gloves (latex gloves should <b>not</b> be used). During application, slowly peel back the release liner under the patch. Patch should remain in place for 60 minutes. Remove patches gently and slowly. Following patch removal, apply cleansing gel to the treatment area and leave in place for at least 1 minute. Remove cleansing gel with a dry wipe and gently wash the area with mild soap and water and dry thoroughly. All treatment materials should be disposed of according to biomedical waste procedures.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145281\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Muscle/Joint pain:</b> Temporary relief of minor aches and pain of muscles and joints associated with backache, strains, sprains, arthritis, bruises, cramps, or muscle stiffness or soreness.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Neuropathic pain:</b> Management of neuropathic pain associated with diabetic neuropathy or postherpetic neuralgia.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25722059\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Burning mouth syndrome (topical); Diabetic neuropathy; Pain associated with psoriasis and intractable pruritus; Oral mucositis (topical)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145316\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Zostrix may be confused with Zestril, Zovirax</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145275\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">The following adverse events occurred with topical patch administration.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&gt;10%: Local: Localized erythema (63%), local pain (42%) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">1% to 10%: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Cardiovascular: Hypertension (2%; transient)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Dermatologic: Papule (6%), local dryness (2%), pruritus (2%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Gastrointestinal: Nausea (5%), vomiting (3%) </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Local: Local pruritus (6%), localized edema (4%), local swelling (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Respiratory: Nasopharyngitis (4%), sinusitis (3%), bronchitis (2%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">&lt;1%, postmarketing, and/or case reports: Abnormal skin odor, application site reactions (includes bruise, dermatitis, desquamation, excoriation, hyperesthesia, inflammation, paresthesia, urticaria), burning sensation of skin, cough, dizziness, dysgeusia, headache, hypoesthesia, peripheral edema, peripheral sensory neuropathy, throat irritation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145285\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to capsaicin, menthol, or any component of the formulation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OTC labeling: When used for self-medication, do not use on wounds, damaged, broken, or irritated skin; do not cover with bandage; do not use in combination with external heat source (eg, heating pad).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145272\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Burns: May cause serious burns (eg, first- to third-degree chemical burns) at the application site. In some cases, hospitalization has been required. Discontinue use and seek medical attention if signs of skin injury (eg, pain, swelling, or blistering) occur following application (FDA Drug Safety Communication, 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks that require mental alertness (eg, operating machinery or driving).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cardiovascular disease: Use with caution in patients with uncontrolled hypertension or a history of cardiovascular events; transient increases in blood pressure due to treatment-related pain have occurred during and after application of RX patch.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Cerebrovascular disease: Use with caution in patients with a history of cerebrovascular events; transient increases in blood pressure due to treatment-related pain have occurred during and after application of RX patch.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Dosage form specific issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (&ge;99 mg/kg/day) have been associated with a potentially fatal toxicity (&ldquo;gasping syndrome&rdquo;) in neonates; the &ldquo;gasping syndrome&rdquo; consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension and cardiovascular collapse (AAP [&quot;Inactive&quot; 1997]; CDC, 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors, 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer&rsquo;s labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Patch: Avoid inhaling airborne material from dried residue. Remove patches gently and slowly to decrease risk of aerosolization; inhalation of airborne capsaicin may result in coughing or sneezing.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Qutenza: If skin not intended to be treated comes in contact with capsaicin, apply provided cleansing gel for one minute and wipe off with dry gauze; then wash the area with soap and water. Post-application pain should be treated with local cooling methods (ice pack) and/or analgesics.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Appropriate use: For external use only; avoid contact with eyes, mouth, genitals, or any or other mucous membranes. Do not use immediately before or after activities such as bathing, swimming, showering, sun bathing, strenuous exercise, steam bath, sauna, or other heat or sunlight exposure to the treated area. Stop use and consult a healthcare provider if excessive redness, blistering burning or irritation develops, symptoms get worse, symptoms persist for &gt;7 days,  symptoms resolve and then recur, or if difficulty breathing or swallowing occurs. Do not handle contact lenses for 1 hour after handling, applying, or removing capsaicin (product specific).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; OTC labeling: Transient burning may occur and generally disappears after several days.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; RX labeling: Do not cover with bandage or compression. Use only on intact skin; do not use on wounds, damaged, broken, infected, sensitive or inflamed skin. Do not apply to face or scalp. Do not use concurrently with other external pain-relieving products.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145307\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of CYP2E1 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145276\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8840&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:0em;display:inline\">There are no known significant interactions.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145277\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13494885\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events have not been observed in animal reproduction studies with capsaicin patch or liquid. Systemic absorption is limited following topical administration of the patch; plasma concentrations are below the limit of detection 3 to 6 hours after the patch is removed.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F10381385\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if capsaicin is excreted in breast milk following topical administration. Some manufacturers recommend not breast-feeding on the day of treatment after the patch has been applied to reduce any potential infant exposure.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145271\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Capsaicin, a transient receptor potential vanilloid 1 receptor (TRPV1) agonist, activates TRPV1 ligand-gated cation channels on nociceptive nerve fibers, resulting in depolarization, initiation of action potential, and pain signal transmission to the spinal cord; capsaicin exposure results in subsequent desensitization of the sensory axons and inhibition of pain transmission initiation. In arthritis, capsaicin induces release of substance P, the principal chemomediator of pain impulses from the periphery to the CNS, from peripheral sensory neurons; after repeated application, capsaicin depletes the neuron of substance P and prevents reaccumulation. The functional link between substance P and the capsaicin receptor, TRPV1, is not well understood.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145284\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Onset of action: OTC products (capsaicin 0.025% to 0.1%): 2 to 4 weeks of continuous therapy; Qutenza patch: 1 week after application</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Absorption: Topical patch (capsaicin 8%): Systemic absorption is transient and low (&lt;5 ng/mL) in approximately one-third of patients when measured following 60-minute application. In patients with quantifiable concentrations, most fell below the limit of quantitation at 3-6 hours postapplication.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Topical patch (capsaicin 8%): 1.64 hours (Babbar 2009)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145286\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cream</b> (Axsain External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.25% (60 g): $32.40</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cream</b> (Capsaicin External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.025% (60 g): $9.95</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cream</b> (Zostrix HP External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.1% (56.6 g): $13.20</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cream</b> (Zostrix Natural Pain Relief External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.033% (56.6 g): $12.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (Capsagel External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.025% (60 g): $4.37</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (Capsagel Extra Strength External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.05% (60 g): $5.37</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Gel</b> (Capsagel Maximum Strength External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.075% (30 g): $5.80</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Qutenza (2 Patch) External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8% (1): $2,010.02</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Kit</b> (Qutenza External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">8% (1): $1,005.01</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Lotion</b> (Bio-Therm Pain Relieving External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.002-10-20% (113.4 g): $449.00</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Lotion</b> (Castiva Warming External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.035% (113 g): $12.42</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Patch</b> (Alivio External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.03-5% (15): $897.50</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Stick</b> (Zostrix-HP External)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">0.075% (1 g): $11.09</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F145287\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Alacapsin (ES);</li>\n      <li>Antidol Forte (UY);</li>\n      <li>Axsain (GB, IE);</li>\n      <li>Capderm (TW);</li>\n      <li>Capsaicina (PY);</li>\n      <li>Capsain-P (IN);</li>\n      <li>Capser (TR);</li>\n      <li>Capsi (BD);</li>\n      <li>Capsicin (ES, VN);</li>\n      <li>Capsidol (ES, MX);</li>\n      <li>Capsika (TH);</li>\n      <li>Capsina (NO, SE);</li>\n      <li>Casacin (TW);</li>\n      <li>Casacine (CO);</li>\n      <li>Diaxen Cream (KR);</li>\n      <li>Dipental Cream (KR);</li>\n      <li>Dolpyc (IT);</li>\n      <li>Emplatre Etoile (CH);</li>\n      <li>Hansamedic Warmtepleister (BE);</li>\n      <li>Hercap (BR);</li>\n      <li>Katrum (ES);</li>\n      <li>Kutenza (UA);</li>\n      <li>Menzza NP (MY);</li>\n      <li>Menzza OA (MY);</li>\n      <li>Moment (BR);</li>\n      <li>Neodor (PT);</li>\n      <li>Ostocin (BD);</li>\n      <li>Pepercin (IR);</li>\n      <li>Picasum (ES);</li>\n      <li>Presyc (CL);</li>\n      <li>Presyc Forte (CL);</li>\n      <li>Qutenza (CZ, DK, GB, HR, HU, IE, LT, LU, MT, NL, PL, QA, RO, TR);</li>\n      <li>Redol (AR);</li>\n      <li>Sensedol (ES);</li>\n      <li>Sensocaps (TR);</li>\n      <li>Topicacin (BD);</li>\n      <li>Zacin (GR, IE);</li>\n      <li>Zostrix Cream (AU, IL, KR, NZ);</li>\n      <li>Zostrix-HP (AU, IL, NZ)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/capsaicin-drug-information/abstract-text/11487763/pubmed\" target=\"_blank\" id=\"11487763\">11487763</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Babbar S, Marier JF, Moukassi MS, et al, &ldquo;Pharmacokinetic Analysis of Capsaicin After Topical Administration of High-Concentration Capsaicin Patch to Patients With Peripheral Neuropathic Pain,&rdquo; <i>Ther Drug Monit</i>, 2009, 31(4):502-10.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/capsaicin-drug-information/abstract-text/19494795/pubmed\" target=\"_blank\" id=\"19494795\">19494795</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Backonja M, Wallace MS, Blonsky ER, et al, &ldquo;NGX-4010, A High-Concentration Capsaicin Patch, for the Treatment of Postherpetic Neuralgia: A Randomised, Double-Blind Study,&rdquo; <i>Lancet Nerurol</i>, 2008, 7(12):1106-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/capsaicin-drug-information/abstract-text/18977178/pubmed\" target=\"_blank\" id=\"18977178\">18977178</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"3760276\"></a>Bernstein JE, Parish LC, Rapaport M, Rosenbaum MM, Roenigk HH Jr. Effects of topically applied capsaicin on moderate and severe psoriasis vulgaris. <i>J Am Acad Dermatol</i>. 1986;15(3):504-507.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/capsaicin-drug-information/abstract-text/3760276/pubmed\" target=\"_blank\" id=\"3760276\">3760276</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bril V, England J, Franklin GM, et al, &quot;Evidence-Based Guideline: Treatment of Painful Diabetic Neuropathy: Report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation,&quot; <i>Neurology</i>, 2011, 76(20):1758-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/capsaicin-drug-information/abstract-text/21482920/pubmed\" target=\"_blank\" id=\"21482920\">21482920</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Buchanan J and Zakrzewska J, &ldquo;Burning Mouth Syndrome,&rdquo; <i>Clin Evid (online)</i>, March 14, 2008. Available at <a href=\"http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2907957/pdf/2008-1301.pdf\" target=\"_blank\">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2907957/pdf/2008-1301.pdf</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/capsaicin-drug-information/abstract-text/19450321/pubmed\" target=\"_blank\" id=\"19450321\">19450321</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Capzasin HP Arthritis Pain Relief Cream (capsaicin) [prescribing information]. Chattanooga, TN: Chattem, Inc; January 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Capzasin Liquid (capsaicin) [prescribing information]. Chattanooga, TN: Chattem, Inc; January 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Capzasin P Arthritis Pain Relief Cream (capsaicin 0.035%) [prescribing information]. Chattanooga, TN: Chattem, Inc; January 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Capzasin Quick Relief Gel (capsaicin 0.025%) [prescribing information]. Chattanooga, TN: Chattem, Inc; January 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol&mdash;United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href=\"http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm\" target=\"_blank\">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a><span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/capsaicin-drug-information/abstract-text/6810084/pubmed\" target=\"_blank\" id=\"6810084\">6810084</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"7688774\"></a>Ellis CN, Berberian B, Sulica VI, et al. A double-blind evaluation of topical capsaicin in pruritic psoriasis. <i>J Am Acad Dermatol</i>. 1993;29(3):438-442.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/capsaicin-drug-information/abstract-text/7688774/pubmed\" target=\"_blank\" id=\"7688774\">7688774</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Food and Drug Administration (FDA) Drug Safety Communication, &quot;Rare Cases of Serious Burns With the Use of Over-the-Counter Topical Muscle and Joint Pain Relievers,&quot; 2012. Available at <a href=\"http://www.fda.gov/Drugs/DrugSafety/ucm318858.htm\" target=\"_blank\">http://www.fda.gov/Drugs/DrugSafety/ucm318858.htm </a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hochberg MC, Altman RD, April KT, et al, &ldquo;American College of Rheumatology 2012 Recommendations for the Use of Nonpharmacologic and Pharmacologic Therapies in Osteoarthritis of the Hand, Hip, and Knee,&rdquo; <i>Arthritis Care Res (Hoboken)</i>, 2012, 64(4):465-74.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/capsaicin-drug-information/abstract-text/22563589/pubmed\" target=\"_blank\" id=\"22563589\">22563589</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Inactive&quot; ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/capsaicin-drug-information/abstract-text/9024461/pubmed\" target=\"_blank\" id=\"9024461\">9024461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Levatio Patch (capsaicin 0.03%) [prescribing information]. Hollywood, FL: Alivio Medical Products; March 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    MaC Patch (capsaicin 0.0375%) [prescribing information]. Madisonville, LA: Solubiomix; April 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    M&iacute;nguez Serra MP, Salort Llorca C, Silvestre Donat FJ. Pharmacological treatment of burning mouth syndrome: A review and update. <i>Med Oral Patol Oral Cir Bucal</i>. 2007;12(4):E299-304.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/capsaicin-drug-information/abstract-text/17664916/pubmed\" target=\"_blank\" id=\"17664916\">17664916</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Petruzzi M, Lauritano D, De Benedittis M, Baldoni M, Serpico R. Systemic capsaicin for burning mouth syndrome: short-term results of a pilot study. <i>J Oral Pathol Med</i>. 2004;33(2):111-114.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/capsaicin-drug-information/abstract-text/14720197/pubmed\" target=\"_blank\" id=\"14720197\">14720197</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Qutenza Patch (capsaicin 8%) [prescribing information]. Ardsley, NY: Acorda Therapeutics, Inc; August 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Relyyt Patch (capsaicin 0.025%) [prescribing information]. Los Angeles, CA: Alexso; November 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Silvestre FJ, Silvestre-Rangil J, Tamarit-Santaf&eacute; C, Bautista D. Application of a capsaicin rinse in the treatment of burning mouth syndrome. <i>Med Oral Patol Oral Cir Bucal</i>. 2012;17(1):e1-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/capsaicin-drug-information/abstract-text/21743415/pubmed\" target=\"_blank\" id=\"21743415\">21743415</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sinelee Patch (capsaicin 0.0375%) [prescribing information]. Canton, MS: OakLock Bio; November 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sinelee Patch (capsaicin 0.05%) [prescribing information]. Canton, MS: OakLock Bio; January 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Solaice Patch (capsaicin 0.05%) [prescribing information]. Daphne, AL: API Solutions; October 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    SR Relief (capsaicin 0.025%) [prescribing information]. Wilmington, DE: Intl. Brand Management; received June 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trixaicin Cream (capsaicin 0.025%) [prescribing information]. Huntsville, AL: Qualitest Pharmaceuticals; March 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Trixaicin HP Cream (capsaicin 0.075%) [prescribing information]. Huntsville, AL: Qualitest Pharmaceuticals; March 2010.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Willcockson HH, Chen Y, Han JE, et al, &ldquo;Effect of Genetic Deletion of the Vanilloid Receptor TRPV1 on the Expression of Substance P in Sensory Neurons of Mice With Adjuvant-Induced Arthritis,&rdquo; <i>Neuropeptides</i>, 2010, 44(4):293-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/capsaicin-drug-information/abstract-text/20303589/pubmed\" target=\"_blank\" id=\"20303589\">20303589</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zostrix HP Arthritis Pain Relief (capsaicin) [prescribing information]. Lake Forest, IL: Akorn, Inc; August 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zostrix HP Foot Pain Relief Cream (capsaicin) [prescribing information]. Lake Forest, IL: Akorn, Inc; August 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zostrix Joint &amp; Arthritis Pain Relief Cream (capsaicin) [prescribing information]. Lake Forest, IL: Akorn, Inc; August 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Zostrix Original Strength (capsaicin) [prescribing information]. Lake Forest, IL: Akorn, Inc; August 2013.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8840 Version 133.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F145291\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F145292\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F145311\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F145293\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F145302\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F145294\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F45627595\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F45627596\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F145280\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F145268\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F145282\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F145281\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25722059\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F145316\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F145275\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F145285\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F145272\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F145307\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F145276\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F145277\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13494885\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F10381385\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F145271\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F145284\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F145286\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F145287\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8840|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=capsaicin-patient-drug-information\" class=\"drug drug_patient\">Capsaicin: Patient drug information</a></li><li><a href=\"topic.htm?path=capsaicin-pediatric-drug-information\" class=\"drug drug_pediatric\">Capsaicin: Pediatric drug information</a></li></ul></div></div>","javascript":null}